| Price | $358.24 |
| Year Range | $244.71 – $378.15 |
| Market Cap | $10.6B |
| PE Ratio | 44.89 |
| Industry | Biotechnology |
What Is Krystal Biotech’s AI Stock Analysis?
Krystal Biotech’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Krystal Biotech’s momentum in near-real time.
Krystal Biotech (KRYS) has an AltIndex AI Score of 58/100, currently a Hold signal. The AI Score distills Krystal Biotech's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Krystal Biotech’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Krystal Biotech — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving KRYS’s AI Score?
Fundamentals
Revenue for the last quarter was $119M. This is an increase of 2.46% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 24.14%, suggesting positive year-over-year growth. Net income for the last quarter was $55M. This represents a decrease of 2.08% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of 42.87%, suggesting positive year-over-year growth. Ebitda for the last quarter was $66M. This is an increase of 4.61% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 36.76%, suggesting positive year-over-year growth. The current P/E ratio is 44.89. This may be considered high, potentially indicating overvaluation and a bearish outlook. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Krystal Biotech’s earnings and insider transactions.
Technicals
Today's stock price is $358.24. This is an increase of 9.74% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 146.72%, suggesting a positive long-term trend. The trend is bullish. The current SMA10 is $359.30, which is higher than the previous SMA10 of $359.22. This indicates a potential upward trend in price movement. The RSI is 75, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Alternative data
Krystal Biotech has an estimated 21 open positions and this number has been stable over the last couple of months indicating a company in a stable position. The business outlook among employees at Krystal Biotech is neutral. Krystal Biotech has an estimate of 10,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Krystal Biotech’s job postings, web traffic and app downloads.
Sentiment & social
Krystal Biotech has 1,300 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Krystal Biotech’s market sentiment.
Frequently Asked Questions: Krystal Biotech AI Stock Analysis
Krystal Biotech's AltIndex AI Score is 58/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Krystal Biotech a Hold (58/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Krystal Biotech — company overview, fundamentals, technicals and alternative data, with a recommendation. See the KRYS AI Score or sign up to read the full thesis.
